Jordanien - engelska - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

إتقان للصناعات الدوائية - itqan pharmaceutical industries - melatonin 5.0 mg/1 tab - 5.0 mg/1 tab

Jordanien - engelska - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

إتقان للصناعات الدوائية - itqan pharmaceutical industries - melatonin 3.0 mg/1 tab - 3.0 mg/1 tab

Jordanien - engelska - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

إتقان للصناعات الدوائية - itqan pharmaceutical industries - melatonin 3.0 mg/1 tab - 3.0 mg/1 tab

Jordanien - engelska - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

إتقان للصناعات الدوائية - itqan pharmaceutical industries - melatonin 5.0 mg/1 tab - 5.0 mg/1 tab

Jordanien - engelska - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

إتقان للصناعات الدوائية - itqan pharmaceutical industries - melatonin 5.0 mg/1 tab - 5.0 mg/1 tab

Israel - engelska - Ministry of Health

neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 5 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; magnesium stearate; titanium dioxide; glucose monohydrate; maltodextrin; iron oxide yellow; lecithin; carmellose sodium - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

rad data australia pty ltd - melatonin, quantity: 1 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate; titanium dioxide; glucose monohydrate; maltodextrin; iron oxide yellow; iron oxide red; lecithin; carmellose sodium - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.

USA - engelska - NLM (National Library of Medicine)

deseret biologicals, inc. - melatonin 6x, 12x, 30x, 200x, 12c, 30c, 60c, 200c - for temporary relief of symptoms related to sleep disorders, seasonal affective disorder, jet lag, and depression.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to sleep disorders, seasonal affective disorder, jet lag, and depression.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.

USA - engelska - NLM (National Library of Medicine)

energique, inc. - melatonin (unii: jl5dk93rcl) (melatonin - unii:jl5dk93rcl) - may temporarily relieve symptoms such as altered sleep patterns.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. may temporarily relieve symptoms such as altered sleep patterns.** **claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.